Business Expanding German Rare Disease Genetic Testing Company CENTOGENE Establishes Japan Office in Tokyo

CENTOGENE GmbH, headquartered in Rostock, Germany, is a biotechnology company founded in 2006 that provides genetic diagnostic services and pharmaceutical industry solutions focused on rare and neurodegenerative diseases on a global scale. The company maintains one of the world's largest biodatabanks dedicated to rare and neurodegenerative diseases, containing data from more than one million individuals, and supports research and development activities for pharmaceutical companies and research institutions through genetic testing, biomarker discovery, and clinical trial support services.

Against the backdrop of market opportunities in Japan's drug discovery sector and government initiatives aimed at strengthening pharmaceutical innovation, the company established its Japanese subsidiary, Centogene Japan Co., Ltd., in Chuo-ku, Tokyo, in January 2026 as a strategic hub for its Asian operations. Going forward, the company plans to strengthen collaboration with Japanese pharmaceutical companies and academic institutions while expanding genetic testing and diagnostic services, biomarker discovery, and clinical trial support in the fields of rare diseases, oncology, and reproductive health.

The JETRO Invest Japan Business Support Center (IBSC) supported the establishment of the company's Japan office by providing temporary office space, tax consultation services, and business matching support, helping facilitate the smooth setup and launch of its operations in Japan.

CENTOGENE's entry into the Japanese market is expected to expand opportunities for collaboration between the company and Japanese pharmaceutical companies and research institutions by leveraging its expertise, data resources, and analytical capabilities in the fields of rare and neurodegenerative diseases. The company's presence is also expected to contribute to the advancement of drug discovery and international research collaboration in these fields.